Key facts
- The FDA is reviewing the safety of the abortion pill mifepristone.
- The review was initiated following a request from anti-abortion groups.
- This review could lead to restrictions on the drug's use and distribution.
- The Trump administration may implement these restrictions.
The Food and Drug Administration (FDA) has initiated a safety review of mifepristone, an abortion pill. This development is seen as a success for anti-abortion organizations and could potentially result in the Trump administration imposing limitations on the drug's availability and distribution methods. The review will involve a retrospective analysis of existing data related to the drug's safety profile.